BCM
PDSB icon

Bridgeway Capital Management’s PDS Biotechnology PDSB Stock Holding History

Bridgeway Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,360
Closed -$103K – 1446
2018
Q1 		$103K Buy
+4,360
New +$1.17M ﹤0.01% 1323

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgeway Capital Management's PDSB Position: Q2 2018 in Review

Bridgeway Capital Management sold out of PDS Biotechnology (PDSB) in Q2 2018, closing a stake of 4,360 shares — an estimated $103K sold.

Bridgeway Capital Management first reported a position in PDSB in Q1 2018 and held it in 1 quarter. The position peaked at $103K in Q1 2018. 43 funds tracked by Wall St. Rank hold PDSB as of Q2 2018.

  • Bridgeway Capital Management reported no remaining PDS Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Bridgeway Capital Management sold 4,360 PDS Biotechnology shares in Q2 2018, an estimated $103K.
  • Bridgeway Capital Management first reported a position in PDS Biotechnology in Q1 2018 and held it in 1 quarter.
  • Bridgeway Capital Management's PDS Biotechnology position peaked at $103K in Q1 2018.
  • 43 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2018.

Based on Bridgeway Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.